| Protocol |
Title |
Status |
Contact |
| 104238 |
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) |
OPEN TO ACCRUAL |
 |
| 103973 |
Phase II Study Evaluating NALIRIFOX versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients with Locally Advanced and Metastatic Pancreatic Adenocarcinoma |
OPEN TO ACCRUAL |
|
| 104174 |
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) |
OPEN TO ACCRUAL |
|
| 104168 |
NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy With Or Without Androgen Deprivation Therapy In Oligometastatic Prostate Cancer (NRG PROMETHEAN) |
OPEN TO ACCRUAL |
|
| 104105 |
A Randomized Phase II Study of Venetoclax and HMA-based Therapies for theTreatment of Older and Unfit Adults With Newly Diagnosed for FLT-3 Mutated Acute Myeloid Leukemia (AML): a MyeloMATCH Treatment Trial |
OPEN TO ACCRUAL |
|
| 104060 |
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients at Risk for Cardiotoxicity (NeoCARD): A Single-arm Phase 2 Trial with a Special Focus on African American and Underserved Patients from NCORP-MU Sites |
OPEN TO ACCRUAL |
|
| 104154 |
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em |
OPEN TO ACCRUAL |
|
| 104165 |
Randomized Phase 2 Trial of Sacituzumab Govitecan With or Without Pembrolizumab in First-line Metastatic PD-L1-negative TNBC |
OPEN TO ACCRUAL |
|
| 104136 |
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) |
OPEN TO ACCRUAL |
|
| 104114 |
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 104186 |
A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH) |
OPEN TO ACCRUAL |
|
| 104132 |
Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma |
OPEN TO ACCRUAL |
|
| 103914 |
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide |
OPEN TO ACCRUAL |
|
| 104022 |
A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients who are not Candidates for Intensive Therapy |
OPEN TO ACCRUAL |
|
| 104200 |
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|
| 103876 |
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) |
OPEN TO ACCRUAL |
|
| 104037 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease. |
OPEN TO ACCRUAL |
|
| 104171 |
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer- Prospect Lung |
OPEN TO ACCRUAL |
|
| 104077 |
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma |
OPEN TO ACCRUAL |
|
| 104020 |
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
OPEN TO ACCRUAL |
|